Streetbeat News

Products Services

IPSC

Century Therapeutics, Inc. (NASDAQ:IPSC) announced the presentation of initial data from its Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas. The data supports the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits. The company's first allogeneic cell therapy product candidate, CNTY-101, is engineered with multiple functionalities designed to enhance its product profile. Preliminary data from a case study shows a complete response maintained in a patient following completion of four 28-day cycles of CNTY-101.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:18 pm

GERN

Geron Corporation (NASDAQ: GERN) has announced the publication of abstracts from the IMerge Phase 3 clinical trial evaluating its investigational telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes (MDS). The data shows consistently higher transfusion independence (TI) response rates than placebo across different risk groups. Imetelstat is currently under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:17 pm

RLYB

Rallybio has announced that its FNAIT Natural History Study abstract has been accepted for presentation at the 65th American Society of Hematology Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:16 pm

JSPR

Jasper Therapeutics (NASDAQ:JSPR) announced positive final results from the Phase 1 study of briquilimab in combination with fludarabine and low-dose irradiation conditioning in older adults with acute myeloid leukemia (AML) in complete remission or myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic cell transplant. The results will be presented at the America Society of Hematology (ASH) 2023 Annual Meeting & Exposition. The study demonstrated that a regimen of briquilimab plus Flu/TBI leads to successful engraftment of donor blood stem cell without the associated short and long-term toxicities.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:16 pm

GRCL

Gracell Biotechnologies Inc. (NASDAQ:GRCL) will present updated results from its ongoing Phase 1 investigator-initiated study of GC012F, a FasTCAR-enabled BCMA and CD19 dual-targeting autologous cell therapy, at the 65th American Society of Hematology Annual Meeting & Exposition. The therapy is being evaluated for hematologic malignancies and autoimmune disease. The updated results include longer-term follow-up and data from additional patients in the study. Gracell believes that GC012F has the potential to revolutionize the treatment landscape for multiple myeloma patients.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:15 pm

BLNK

Blink Charging UK has announced the launch of its advanced vehicle-to-grid charger, the EQ 200, in the UK and Ireland. The EQ 200 is a scalable and bi-directional charging solution with vehicle-to-grid (V2G) capability and can be used as part of smart energy management systems.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:15 pm

JEWL

Adamas One Corp. (Nasdaq: JEWL) has announced the initial delivery of high-quality, single-crystal, lab-grown colorless diamonds. The company's R&D efforts have led to the creation of D, E, and F diamonds, which are considered colorless. CEO Jay Grdina believes their proprietary machinery and processes give them a competitive advantage in the jewelry, tech, and industrial sectors. The company plans to expand production as lab-grown diamonds now represent over 50% of diamond sales in the US.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:14 pm

AFRM

AMZN

Amazon (AMZN) and Affirm (AFRM) have expanded their partnership, making Affirm the first pay-over-time option available at checkout on Amazon Business. The new payment option will be available to all eligible Amazon Business sole proprietor customers by Black Friday. This marks the launch of Affirm's new B2B pay-over-time solution dedicated to serving sole proprietors.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:13 pm

AUTL

Autolus Therapeutics plc (NASDAQ:AUTL) will present clinical data updates at the American Society of Hematology Annual Meeting 2023. The presentations will include updates on the ongoing FELIX Phase Ib/II study and MCARTY Phase I Study, as well as data demonstrating the robustness of obe-cel's manufacturing process. The company expects to file a BLA later this year.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:13 pm

AMZN

NVDA

TSM

Amazon's cloud computing service, Amazon Elastic Compute Cloud (EC2), has introduced a new feature called EC2 Capacity Blocks for ML to address the global GPU shortage. The feature allows users to reserve GPU instances for specific durations, providing a solution for the growing demand for GPU capacity in machine learning applications. The service offers access to Nvidia's H100 Tensor Core GPUs in EC2 UltraClusters. Nvidia and its key supplier, Taiwan Semiconductor Manufacturing Company, are struggling to keep up with the AI demand, leading to higher GPU prices.

Portfolio Pulse from Anusuya Lahiri

November 02, 2023 | 1:13 pm